title: Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.
abstract: To investigate GH secretory capacities in patients with Turner's syndrome, GHRH, arginine, L-dopa and pyridostigmine (PD) were administered singly and GHRH was administered sequentially for 3 days. In addition, plasma GH and TSH responses to GHRH and TRH after pretreatment with PD were analyzed to investigate whether the hypothalamic cholinergic somatostatinergic system functioned normally. The maximal GH responses to GHRH, L-dopa and PD were significantly smaller in Turner's syndrome (no.=14) than in normal short children (NSC, no.=14). However, there was no difference in plasma GH responses to arginine between the two groups. In ten patients with Turner's syndrome, the plasma GH response to GHRH did not improve even after the sequential 3-day administrations. Although plasma GH and TSH responses to GHRH and TRH were significantly enhanced by the pretreatment of PD in NSC (no.=12), these responses were not enhanced in Turner's syndrome. Plasma GH response to GHRH in Turner's syndrome with normal body fat was still significantly lower than in NSC. It is therefore concluded that somatotroph sensitivity to GHRH is decreased in Turner's syndrome and that this may be due to the primary defects of the somatotrophs rather than to the increased body fat. In addition, the network of cholinergic-somatostatinergic systems seemed to be impaired in these patients, while the activity of hypothalamic somatostatin neurons was thought to be maintained.
authors.affiliation: Hanew Endocrine Clinic, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hanew
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: A
authors.initials: A
authors.lastname: Utsumi
mesh_terms: D000293:Adolescent; D000328:Adult; D001120:Arginine; D001827:Body Height; D002648:Child; D002800:Cholinesterase Inhibitors; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage; D019382:Human Growth Hormone / Q000097:blood*; D006801:Humans; D007980:Levodopa; D011729:Pyridostigmine Bromide / Q000008:administration & dosage; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D014424:Turner Syndrome / Q000097:blood*
chemical_list: D002800:Cholinesterase Inhibitors; D019382:Human Growth Hormone; D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; D011729:Pyridostigmine Bromide